A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.

Robert W HollowayPremal ThakerAlberto A MendivilSarfraz AhmadAhmed N Al-NiaimiJames BarterTiffany BeckSetsuko K ChambersRobert L ColemanSarah M CraftonErin CraneEskander RamezSharad GhamandeWhitney GraybillThomas HerzogMegan Dr IndermaurVeena S JohnLisa LandrumPeter C LimJoseph A LucciMichael McHaleBradley J MonkKathleen Nadine MooreRobert MorrisDavid M O'MalleyThomas J ReidDebra L RichardsonPeter G RoseJennifer M ScaliciDan-Arin SilasiKrishnansu TewariEdward W Wang

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)

NCT05281471.

Keyphrases

phase iii
open label
locally advanced
double blind
clinical trial
metastatic colorectal cancer
phase ii
placebo controlled
randomized controlled trial
squamous cell carcinoma
rectal cancer
radiation therapy